NCT00109291终止2 期
A Phase 2a, Randomized, Double-blind, Placebo-controlled, Sequential Dose Escalation Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Patients With Chronic Kidney Disease Who Are Not on Dialysis and Who Have Not Had Prior Erythropoiesis Stimulating Agent (ESA) Treatment
Affymax1 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2005年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 17
- 试验地点
- 1
- 主要终点
- Incidence of adverse events and serious adverse events
研究概览
简要总结
To evaluate the safety profile of single intravenous (IV) dose levels of peginesatide in participants with chronic kidney disease(CKD) not on dialysis.
详细描述
This was a Phase 2a, randomized, double-blind, placebo-controlled, sequential dose escalation study conducted at a single clinical center. The study was designed to evaluate up to 6 treatment cohorts of 9 participants with CKD not on dialysis in the first cohort and 5 participants in each subsequent cohort. In each treatment cohort, participants were randomly assigned to receive either a single dose of peginesatide (n=7 in the first cohort, n=4 in subsequent cohorts) or placebo (n=2 in the first cohort, n=1 in subsequent cohorts). Participants were followed for a minimum of 28 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant is informed of the investigational nature of this study and has given written, witnessed informed consent in accordance with institutional, local, and national guidelines;
- •Males or females ≥ 18 and ≤ 75 years of age. Pre-menopausal females (with the exception of those who are surgically sterile) must have a negative pregnancy test at screening; those who are sexually active must practice an adequate form of contraception for at least 2 weeks prior to study start, and must be willing to continue contraception for at least 4 weeks after receiving study drug;
- •Chronic kidney disease stage 3 or 4 (glomerular filtration rate [GFR] of 15-60 milliliter per minute (mL/min) within 28 days prior to administration of study drug,) not requiring dialysis;
- •Two hemoglobin values of ≥ 9 grams per deciliter (g/dL) and ≤ 11 g/dL within 14 days prior to administration of study drug, with one of the values drawn within 7 days prior to administration of study drug;
- •One serum ferritin level ≥ 100 micrograms per liter (µg/L) and one transferrin saturation ≥ 20% within 28 days prior to administration of study drug;
- •One serum folate level above the lower limit of normal within 28 days prior to administration of study drug;
- •One vitamin B12 level above the lower limit of normal within 28 days prior to administration of study drug;
- •Weight ≥ 45 kg within 28 days prior to administration of study drug;
- •One white blood cell count ≥ 3.0 x 10^9/L within 28 days prior to administration of study drug; and
- •One platelet count ≥ 140 x 10^9/L and ≤ 500 x 10^9/L within 28 days prior to administration of study drug.
排除标准
- •Prior treatment with any erythropoiesis stimulating agent;
- •History of pure red cell aplasia;
- •Red blood cell transfusion within 3 months prior to study drug administration;
- •Hemoglobinopathy (e.g., homozygous sickle-cell disease, thalassemia of all types, etc.);
- •Hemolysis based on medical judgment;
- •Chronic, uncontrolled, or symptomatic inflammatory disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, etc.);
- •C Reactive Protein (CRP) greater than 30 mg/L within 14 days prior to administration of study drug;
- •Significant infection within 4 weeks prior to study drug administration, per Investigator's clinical judgment ;
- •Febrile illness within 7 days prior to administration of study drug;
- •Uncontrolled or symptomatic secondary hyperparathyroidism;
- •Poorly controlled hypertension within 4 weeks prior to study drug administration, per Investigator's clinical judgment (e.g. systolic ≥ 170mm Hg, diastolic ≥ 100 mm Hg on repeat readings);
- •Epileptic seizure in the 6 months prior to study drug administration;
- •Chronic congestive heart failure (New York Heart Association Class IV);
- •High likelihood of early withdrawal or interruption of the study (e.g., myocardial infarction, severe or unstable coronary artery disease, stroke, respiratory, autoimmune, neuropsychiatric, or neurological abnormalities, liver disease including active hepatitis B or C, active HIV disease, or any other clinically significant medical diseases or conditions within the past 6 months that may, in the Investigator's opinion, interfere with assessment or follow-up of the patient);
- •Malignancy (except non-melanoma skin cancer);
- •Life expectancy < 12 months;
- •Anticipated elective surgery during the study period;
- •Previous exposure to any investigational agent within 4 months prior to administration of study drug or planned receipt during the study period.
研究组 & 干预措施
Peginesatide 0.05 mg/kg
Experimental
Single peginesatide dose of 0.05 mg/kg administered intravenously.
干预措施: peginesatide (Drug)
Placebo
Placebo Comparator
Single injection of placebo administered intravenously
干预措施: Placebo (Drug)
Peginesatide 0.025 mg/kg
Experimental
Single peginesatide dose of 0.025 milligram per kilogram (mg/kg) administered intravenously.
干预措施: peginesatide (Drug)
Peginesatide 0.10 mg/kg
Experimental
Single peginesatide dose of 0.10 mg/kg administered intravenously.
干预措施: peginesatide (Drug)
结局指标
主要结局
Incidence of adverse events and serious adverse events
时间窗: 28 days
次要结局
- Pharmacokinetic parameters(28 days)
- Pharmacodynamic parameters(28 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Peginesatide for Maintenance Treatment of Anemia in Participants on HemodialysisChronic Kidney DiseaseAnemiaChronic Renal FailureNCT00434330Affymax91
终止
1 期
Single Dose PG102 in Patients With Active Psoriatic ArthritisArthritis, PsoriaticNCT00787137PanGenetics UK Limited17
已完成
2 期
Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESAChronic Kidney DiseaseAnemiaChronic Renal FailureNCT00680043Affymax114
招募中
2 期
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)Head and Neck CancerUnknown Primary CancerHead and Neck Squamous Cell CarcinomaNCT05576974University of Texas Southwestern Medical Center120
已完成
2 期
Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.AnemiaNCT00752609Takeda102